TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22515360

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, Levofloxacin 500 mg once daily for 7 days
Number of subjects: 128

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, Tetracycline 500 mg four times daily for 14 days
Number of subjects: 128
Study: 20513227

Group type: EXPERIMENTAL
Intervention: Once-daily extended-release methylphenidate (MPH)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Twice-daily immediate-release methylphenidate (MPH)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Actigraphy during structured situations
Number of subjects: 49
Study: 18541180

Group type: EXPERIMENTAL
Intervention: Letter invitation to re-enroll
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Letter with ethnic-specific content invitation to re-enroll
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Letter and telephone call invitation to re-enroll
Number of subjects: 2400

Group type: COMPARATOR
Intervention: No invitation to re-enroll
Number of subjects: 2400
Study: 16410734

Group type: EXPERIMENTAL
Intervention: Active treatment with diuretic indapamide and angiotensin-converting enzyme inhibitor perindopril if required
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 12818954

Group type: EXPERIMENTAL
Intervention: Bupivacaine-loaded microcapsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aqueous bupivacaine
Number of subjects: 0
Study: 10685583

Group type: EXPERIMENTAL
Intervention: Ground-level oxygen (GLO) treatment for 2 hours
Number of subjects: 801
Study: 9332329

Group type: COMPARATOR
Intervention: Conventional amphotericin B 1 mg/kg/d (c‐AMB)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 1 mg/kg/d (L‐AMB1)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 3 mg/kg/d (L‐AMB3)
Number of subjects: 338
Study: 8229130

Group type: EXPERIMENTAL
Intervention: Continued testicular androgen suppression
Number of subjects: 341

Group type: COMPARATOR
Intervention: Discontinued exogenous endocrine therapy
Number of subjects: 341
Study: 3094063

Group type: EXPERIMENTAL
Intervention: Desamino-D-arg8-vasopressin (DDAVP) 20 or 60 micrograms/subject
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol (EtOH) 0.33 ml/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol (EtOH) 1.0 ml/kg
Number of subjects: 0
Study: 30903329

Group type: EXPERIMENTAL
Intervention: 800 ml PEG + Asc (Regimen A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 600 ml PEG + Asc (Regimen B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400 ml PEG + Asc (Regimen C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regimen A vs Regimen B
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regimen A vs Regimen C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 60
Study: 28659201

Group type: EXPERIMENTAL
Intervention: Embrace intervention (care and support from an elderly-care team including a specialist in Gerontology, a district nurse, and a social worker)
Number of subjects: 1456

Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Caregivers' report on implementation of integrated care
Number of subjects: 1456
Study: 26162662

Group type: EXPERIMENTAL
Intervention: High and moderate baseline expectancies of success
Number of subjects: 118

Group type: COMPARATOR
Intervention: Low baseline expectancies of success
Number of subjects: 118
Study: 24473589

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21714641

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (CT) screening
Number of subjects: 53454

Group type: COMPARATOR
Intervention: Single-view posteroanterior chest radiography
Number of subjects: 53454
Study: 18657938

Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: Assessment control group
Number of subjects: 198
Study: 17133893

Group type: EXPERIMENTAL
Intervention: Meaning-centered psycho-educational group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15286133

Group type: EXPERIMENTAL
Intervention: Therapies directed at correcting demineralization-remineralization imbalance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic technologies under development
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outcome indices reflecting cavitation and lesion status
Number of subjects: 0
Study: 11217014

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (delayed bedtime or early awakening)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Zolpidem-induced sleep (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 9273107

Group type: EXPERIMENTAL
Intervention: Highly purified human folliculostimulin (FSH-HP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (hMG)
Number of subjects: 0
Study: 8486328

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB) 250 mg
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB) 1,000 mg
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study: 3813061

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% in 8% glucose (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% in 8% glucose (Group 3)
Number of subjects: 60
Study: 31601448

Group type: EXPERIMENTAL
Intervention: Cartoon illustration
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Anatomical drawing
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Computed tomography scan (CT)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Illustrated leaflets (any style)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control leaflet (no images)
Number of subjects: 204
Study: 29638188

Group type: EXPERIMENTAL
Intervention: Production-learning condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comprehension-learning condition
Number of subjects: 0
Study: 26511988

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 150
Study: 24162462

Group type: EXPERIMENTAL
Intervention: Emulsified isoflurane (EI) at doses starting from 0.3 mg/kg to 64.6 mg/kg
Number of subjects: 78
Study: 22305834

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 946

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 946
Study: 20299628

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg bid + active theophylline capsules (plasma level of 8.8-12.4 mg/L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhaled fluticasone propionate (FP) alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo theophylline capsules + inhaled placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination treatment with FP and theophylline
Number of subjects: 30
Study: 18577010

Group type: EXPERIMENTAL
Intervention: MSG substitutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: MSG
Number of subjects: 10
Study: 16022206

Group type: EXPERIMENTAL
Intervention: E-mail intervention promoting physical activity and nutrition (1 message per week for 12 weeks)
Number of subjects: 2121

Group type: COMPARATOR
Intervention: Control group (no weekly messages)
Number of subjects: 2121
Study: 12449309

Group type: EXPERIMENTAL
Intervention: Calcium sulfate as a graft/barrier
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Calcium sulfate plus doxycycline
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 17
Study: 10347528

Group type: EXPERIMENTAL
Intervention: Catheter valves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional urinary drainage systems
Number of subjects: 0
Study: 7856777

Group type: EXPERIMENTAL
Intervention: Community-level, multi-channel, 4-year intervention
Number of subjects: 20047
Study: 1961958

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Thiopentone 5 mg/kg (n = 40)
Number of subjects: 80
Study: 6789294

Group type: EXPERIMENTAL
Intervention: Alterations in PEEP (Positive End-Expiratory Pressure)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alterations in PIP (Peak Inspiratory Pressure)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alterations in inspiratory/expiratory ratio
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Increases in PEEP and decreases in PIP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decreases in PEEP and increases in PIP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alterations in PIP
Number of subjects: 20
Study: 30786162

Group type: EXPERIMENTAL
Intervention: Meloxicam IV 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29125976

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 430
Study: 26879101

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 100
Study: 24462012

Group type: EXPERIMENTAL
Intervention: Group medical clinics
Number of subjects: 239

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 239
Study: 23039801

Group type: EXPERIMENTAL
Intervention: CO₂
Number of subjects: 141

Group type: COMPARATOR
Intervention: Air
Number of subjects: 141
Study: 20302385

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) referrals
Number of subjects: 800

Group type: COMPARATOR
Intervention: Regular face-to-face hospital referrals
Number of subjects: 800
Study: 17356966

Group type: EXPERIMENTAL
Intervention: Mailed reminders alone
Number of subjects: 10354

Group type: EXPERIMENTAL
Intervention: Mailed reminders with physician prompts
Number of subjects: 10354

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10354
Study: 16332659

Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched cereal bars (50 mg/d)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo cereal bars
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Isoflavone treatment
Number of subjects: 117
Study: 12444863

Group type: EXPERIMENTAL
Intervention: PSV protocol (n = 62)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: VSV protocol (n = 60)
Number of subjects: 182

Group type: COMPARATOR
Intervention: No protocol (n = 60)
Number of subjects: 182
Study: 10980840

Group type: EXPERIMENTAL
Intervention: Direct thrombin inhibitors (hirudin, hirulog) as adjuncts to thrombolytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hirudin administered at a mean of 34 and 50 minutes after thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct thrombin inhibitors administered prior to thrombolysis
Number of subjects: 0
Study: 7594905

Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated control
Number of subjects: 0
Study: 2183052

Group type: EXPERIMENTAL
Intervention: Chemotherapy with irradiation (27 Gy) of the involved field
Number of subjects: 129

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 129
Study: 6775956

Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Probenecid in patients with renal insufficiency
Number of subjects: 52
Study: 30270415

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 120
Study: 28339738

Group type: EXPERIMENTAL
Intervention: Tapering of TNF inhibitors (TNFi)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 171
Study: 25588456

Group type: EXPERIMENTAL
Intervention: L-dopa (100/25 mg of l-dopa/carbidopa daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24090447

Group type: EXPERIMENTAL
Intervention: Visuotemporal cue
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Visual cue
Number of subjects: 33

Group type: COMPARATOR
Intervention: Uncued condition
Number of subjects: 33
Study: 21345996

Group type: EXPERIMENTAL
Intervention: HD-SDM
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: mETDRS
Number of subjects: 123

Group type: COMPARATOR
Intervention: ND-SDM
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 123
Study: 19835117

Group type: EXPERIMENTAL
Intervention: Acupuncture (Group A)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Group B)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Acupuncture plus acupoint injection (Group C)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus acupoint injection (Group D)
Number of subjects: 187
Study: 17919229

Group type: EXPERIMENTAL
Intervention: Interferon and lamivudine combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pegylated interferon monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional interferon monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional interferon and lamivudine combination therapy
Number of subjects: 0
Study: 15482039

Group type: EXPERIMENTAL
Intervention: 1st grade single- and multiple-rater screening models
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Early screening
Number of subjects: 396
Study: 15635354

Group type: EXPERIMENTAL
Intervention: Juice reconstituted from frozen concentrate on day 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Juice reconstituted from frozen concentrate on day 8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chilled juice on day 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chilled juice on day 8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Juice from frozen concentrate on day 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Juice from frozen concentrate on day 8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postprandial plasma TBARS and vitamin C
Number of subjects: 0
Study: 10329338

Group type: COMPARATOR
Intervention: MRRH system (reference group)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 277
Study: 8858026

Group type: EXPERIMENTAL
Intervention: Comprehensive injury prevention program
Number of subjects: 0
Study: 1928978

Group type: EXPERIMENTAL
Intervention: Routine 72-hour catheter exchange with implantable collagen cuff
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Routine 72-hour catheter exchange without implantable collagen cuff
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Routine 7-day catheter exchange with implantable collagen cuff
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Routine 7-day catheter exchange without implantable collagen cuff
Number of subjects: 85
Study: 7117677

Group type: EXPERIMENTAL
Intervention: Nabumetone (1 g at night)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Naproxen (250 mg b.i.d.)
Number of subjects: 25
Study: 29664836

Group type: EXPERIMENTAL
Intervention: Low LY30
Number of subjects: 549

Group type: COMPARATOR
Intervention: Moderate PAP
Number of subjects: 549

Group type: COMPARATOR
Intervention: Low PAP
Number of subjects: 549
Study: 28877841

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy for health anxiety (CBT-HA) - 4 to 10 sessions of 1-hour CBT-HA
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy for health anxiety (CBT-HA)
Number of subjects: 444
Study: 25343949

Group type: EXPERIMENTAL
Intervention: Baseline fibroblast growth factor 23 levels
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Adjustment for clinical risk factors and baseline eGFR
Number of subjects: 590
Study: 24796587

Group type: EXPERIMENTAL
Intervention: Slow eye movement (SEM) analysis during the multiple sleep latency test (MSLT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Slow eye movement (SEM) analysis during the maintenance of wakefulness test (MWT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of SEM latency with sleep latency at MSLT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of SEM latency with sleep latency at MWT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of Epworth Sleepiness Scale score with SEM latency at MSLT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of Epworth Sleepiness Scale score with SEM latency at MWT
Number of subjects: 20
Study: 22461443

Group type: EXPERIMENTAL
Intervention: Live High-Train Low (LHTL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19037576

Group type: EXPERIMENTAL
Intervention: High homocysteine (highest tertile)
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Middle homocysteine (middle tertile)
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Lowest homocysteine (lowest tertile)
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: MTHFR genotype variation
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Homocysteine
Number of subjects: 1213
Study: 17917504

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan (IRBE) + Quinapril (QUIN)
Number of subjects: 0
Study: 15389230

Group type: EXPERIMENTAL
Intervention: Sibrafiban
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 15904
Study: 11264066

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam spray (4 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 54
Study: 9681343

Group type: EXPERIMENTAL
Intervention: Topical 1% SDZ ASM 981 cream applied twice daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Topical 1% SDZ ASM 981 cream applied once daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 34
Study: 7972616

Group type: EXPERIMENTAL
Intervention: Acute psychological stressor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-stressor control group
Number of subjects: 0
Study: 30584532

Group type: EXPERIMENTAL
Intervention: Maximum Swing Flexion (MSF)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gait Symmetry (GS)
Number of subjects: 6
Study: 25758624

Group type: EXPERIMENTAL
Intervention: 5% glucose-containing intravenous solution (D5LR)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Lactated Ringer's (LR)
Number of subjects: 309
Study: 25677670

Group type: EXPERIMENTAL
Intervention: Keratograph 5M
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fourier-domain optical-coherence tomography (Spectralis OCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between Keratograph and Spectralis OCT
Number of subjects: 30
Study: 23111617

Group type: EXPERIMENTAL
Intervention: Social dinosaur robot
Number of subjects: 24

Group type: COMPARATOR
Intervention: Human interaction partner
Number of subjects: 24

Group type: COMPARATOR
Intervention: Touchscreen computer game
Number of subjects: 24
Study: 21358360

Group type: EXPERIMENTAL
Intervention: Fluid fill
Number of subjects: 92

Group type: COMPARATOR
Intervention: Air fill
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 23-gauge instrumentation
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 25-gauge instrumentation
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Comparison of 23-gauge vs 25-gauge
Number of subjects: 92
Study: 18430844

Group type: EXPERIMENTAL
Intervention: Automated measurement
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual 2D measurement by observer 1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual 3D measurement by observer 1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual 2D measurement by observer 2
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual 3D measurement by observer 2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Automated measurement for phantom data
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Automated measurement for patient data
Number of subjects: 16
Study: 16485727

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) treatment (1200 mg/day in 3 divided doses for 3 days followed by 300 mg i.v. after anaesthesia induction)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no PTX treatment)
Number of subjects: 25
Study: 14515290

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 100
Study: 10866882

Group type: EXPERIMENTAL
Intervention: tranexamic acid, 10 mg. kg(‐1). h(‐1)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: epsilon‐aminocaproic acid, 16 mg. kg(‐1). h(‐1)
Number of subjects: 132

Group type: COMPARATOR
Intervention: placebo (isotonic saline)
Number of subjects: 132
Study: 9083732

Group type: EXPERIMENTAL
Intervention: New brochures
Number of subjects: 371

Group type: COMPARATOR
Intervention: Old brochure
Number of subjects: 371
Study: 8450440

Group type: EXPERIMENTAL
Intervention: 3.2 mm incision
Number of subjects: 196

Group type: COMPARATOR
Intervention: 5.0 mm incision
Number of subjects: 196

Group type: COMPARATOR
Intervention: 6.0 mm incision
Number of subjects: 196

Group type: COMPARATOR
Intervention: 5.0 mm and 6.0 mm incisions
Number of subjects: 196
Study: 3092780

Group type: EXPERIMENTAL
Intervention: Alprazolam treatment in 8 patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Rebreathing with CO2
Number of subjects: 37
Study: 29663908

Group type: EXPERIMENTAL
Intervention: Glass carbomer cement
Number of subjects: 33

Group type: COMPARATOR
Intervention: High-viscosity glass ionomer cement
Number of subjects: 33
Study: 27161539

Group type: EXPERIMENTAL
Intervention: Complete lymph node dissection
Number of subjects: 240

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 240